Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q1 2022 call → NOWe need to determine if management's forward account is substantially about counterparties' own growth/expansion, with the company already embedded, and that growth is early and large relative to the company. Looking at the transcript: Management discusses lithium, iodine, nitrates. They talk about their own capacity expansions, investments, etc. They mention LG partnership: "we signed, for example, an agreement with LG... we believe we can jointly explore new businesses... we will study together... Most of this investment could be very good idea to do it in Chile... we will review our investment plan... we should update our projections following that review." This is about exploring new businesses, not yet concrete. They also mention Mt. Holland project expansion decision. They talk about demand recovery, but not specific counterparties' own ramps. They mention "we are seeing that there is a recovery in the demand" for lithium, but that's general. They don't describe specific customers' build-outs. They talk about their own production increases. The iodine and nitrates discussion is about their own capacity and market conditions. No narration of counterparties' own scaling as the driver. The LG agreement is exploratory, not yet embedded. So answer NO. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.